Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) insider Joseph Shulman sold 45,921 shares of the stock in a transaction on Wednesday, November 18th. The stock was sold at an average price of $119.90, for a total value of $5,505,927.90. Following the completion of the transaction, the insider owned 10,461 shares of the company’s stock, valued at approximately $1,254,273.90. This trade represents a 81.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Rhythm Pharmaceuticals Price Performance
Shares of Rhythm Pharmaceuticals stock opened at $112.36 on Friday. Rhythm Pharmaceuticals, Inc. has a 12 month low of $74.50 and a 12 month high of $122.20. The business has a fifty day simple moving average of $98.08 and a two-hundred day simple moving average of $97.67.
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($0.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.10. The firm had revenue of $92.13 million for the quarter, compared to the consensus estimate of $85.56 million. Rhythm Pharmaceuticals had a negative net margin of 69.03% and a negative return on equity of 171.16%. The company’s revenue was up 79.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.82) EPS. On average, sell-side analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.90 earnings per share for the current year.
Institutional Investors Weigh In On Rhythm Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in shares of Rhythm Pharmaceuticals by 36.3% during the second quarter. GAMMA Investing LLC now owns 364 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in shares of Rhythm Pharmaceuticals during the second quarter valued at $51,000. EverSource Wealth Advisors LLC increased its holdings in Rhythm Pharmaceuticals by 106.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 549 shares of the company’s stock worth $48,000 after buying an additional 283 shares in the last quarter. Pinnacle Wealth Planning Services Inc. increased its holdings in Rhythm Pharmaceuticals by 894.0% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 666 shares of the company’s stock worth $63,000 after buying an additional 599 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in Rhythm Pharmaceuticals by 9.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the company’s stock worth $155,000 after buying an additional 136 shares in the last quarter.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on RYTM. Needham & Company LLC cut their price objective on shares of Rhythm Pharmaceuticals from $130.00 to $114.00 and set a “buy” rating on the stock in a report on Tuesday, November 3rd. HC Wainwright lifted their target price on shares of Rhythm Pharmaceuticals from $105.00 to $130.00 and gave the company a “buy” rating in a report on Monday, October 12th. Leerink Partners assumed coverage on shares of Rhythm Pharmaceuticals in a report on Monday, September 14th. They set an “outperform” rating and a $133.00 target price for the company. Citigroup reissued a “market outperform” rating on shares of Rhythm Pharmaceuticals in a research report on Friday. Finally, Deutsche Bank began coverage on Rhythm Pharmaceuticals in a research note on Friday, August 28th. They issued a “hold” rating and a $120.00 price target on the stock. Eighteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $141.67.
Get Our Latest Research Report on RYTM
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.
Recommended Stories
- Five stocks we like better than Rhythm Pharmaceuticals
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
